Sofinnova Partners

SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.

Berry Street operates an online telehealth platform that specializes in nutrition therapy for various health conditions, including disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes. The platform connects patients with board-certified dietitians, facilitating care through video and chat services. By partnering with numerous insurance plans, Berry Street ensures that patients can access these essential services without incurring out-of-pocket expenses, ultimately helping them achieve their health goals and enhance their quality of life.

nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Cure51 is focused on building a comprehensive database of cancer survivors to harness their unique biological characteristics in the pursuit of new cancer therapies. The company develops a clinical and molecular database aimed at expediting drug discovery by analyzing the biology of long-term cancer survivors. This approach allows researchers to identify potential targets for drug development by decoding genetic information from various sources, including biopsies, blood tests, and imaging. By leveraging insights gained from this data, Cure51 aims to contribute to the formulation of innovative treatments for cancer.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Leucid Bio is a biotechnology company focused on developing innovative cell therapies for patients with refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is guided by a seasoned management team possessing both scientific and commercial expertise. The company has a strong partnership with King's College, granting it exclusive access to a wealth of scientific, clinical, and manufacturing resources, particularly from Dr. Maher and his team of immuno-oncology specialists. By specializing in advanced CAR T-cell therapies, Leucid Bio aims to enhance treatment outcomes and provide durable responses for patients who have limited or no treatment options available.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

CorVent Medical specializes in the development, manufacturing, and marketing of ventilation and respiratory products aimed at addressing acute, sub-acute, and home care needs. The company has created the RESPOND ventilation platform, a compact and lightweight ventilator designed for quick deployment in various clinical settings and stockpiles. Weighing only 15 pounds, the RESPOND ventilator meets the ICU primary ventilation standard and is engineered for maintenance-free operation with a long shelf life, ensuring reliability and low total ownership costs. By utilizing advanced technologies, CorVent Medical provides healthcare providers with cost-effective solutions to manage respiratory insufficiency, allowing them to efficiently focus on critical patient care.

PinCell is a biotechnology company dedicated to the research and development of innovative treatments for dermatological diseases, particularly those that are rare or orphan conditions. The firm's focus lies in identifying and targeting novel pathways associated with the underlying mechanisms of inflammatory and neoplastic skin disorders. By concentrating on these new therapeutic targets, PinCell aims to create effective therapies that address unmet medical needs within the field of dermatology. Through its research efforts, the company seeks to enable the discovery of new therapeutic molecules that can improve patient outcomes in skin disease management.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

Epsilen Bio is developing a transformative therapy known as Epigenetic Silencing to treat human diseases. Epsilen Bio's mission is to develop therapies for patients affected by underserved medical conditions, through stable genomic epigenetic silencing of genes involved in pathological processes. The company was founded in December 2019 and based in Milan, Italy.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Redx Pharma is a UK-based biotechnology company founded in 2010, specializing in drug discovery and development for oncology and fibrotic diseases. The company focuses on creating novel small molecule drugs aimed at addressing significant unmet medical needs. Its product pipeline includes several promising candidates such as RXC004, a porcupine inhibitor in Phase I clinical development for various cancers; ROCK2, targeting diabetic nephropathy and idiopathic pulmonary fibrosis; and RXC005, a reversible inhibitor of Bruton’s tyrosine kinase. Additionally, Redx Pharma collaborates with global pharmaceutical companies, including a research partnership with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through subsidiaries dedicated to oncology, anti-infectives, and immunology, generating revenue from scientific programs and research collaborations.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Castle Biosciences, Inc. is a commercial-stage biotechnology company focused on developing and commercializing diagnostic and prognostic tests for dermatological cancers. The company's lead product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis by analyzing biological information from 31 genes in tumor tissue. In addition, Castle Biosciences offers the DecisionDx-UM test, which predicts metastasis risk in uveal melanoma patients, and is developing two late-stage products targeting cutaneous squamous cell carcinoma and suspicious pigmented lesions. The company's tests provide personalized, clinically actionable genomic information to assist physicians and patients in making informed treatment decisions. Founded in 2007 and headquartered in Friendswood, Texas, Castle Biosciences aims to significantly impact cancer diagnosis and management through its innovative diagnostic solutions.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, specializes in the development of drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016, the company operates as a subsidiary of Zambon S.p.A. Breath Therapeutics focuses on innovative inhalation therapies that combine novel formulations of existing drugs with advanced inhalation technology, specifically targeting rare respiratory conditions with significant unmet medical needs. Their product offerings include a liposomal formulation of cyclosporine A for inhalation, delivered via a high-performance nebulizer that enhances drug concentration in the lungs while reducing systemic exposure. This approach aims to improve treatment efficacy and safety for patients suffering from life-threatening pulmonary diseases.

myTomorrows is an independent organization based in the Netherlands that focuses on improving access to treatments for patients with unmet medical needs. By providing both patients and their healthcare providers with comprehensive information about treatment options worldwide, myTomorrows aims to eliminate barriers related to understanding and administrative processes. The organization collaborates with medicine manufacturers to develop strategies for early access to innovative therapies, ensuring that patients who have exhausted conventional treatment options can find and access promising medicines still in development. Additionally, myTomorrows has created a Knowledge Base that compiles extensive medical and clinical data, offering a clear overview of the entire clinical development pipeline.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

MD Start is an incubator and fund dedicated to medical technologies. MD Start creates, develops, and operates medical projects, turning them into new companies with both strategic and hands-on approaches, in order to bring them to investment stage and commercial development.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Delinia, Inc. is a biotechnology company based in San Francisco, California, focused on developing novel therapeutics for autoimmune and inflammatory diseases. Founded in 2014, the company’s lead program features a molecule that selectively potentiates and expands regulatory T cells (Tregs), which play a vital role in maintaining self-tolerance and immune system balance. With a team of scientific founders and experienced executives, Delinia aims to advance its therapeutics through clinical development, providing enhanced treatment options for patients suffering from autoimmune conditions. In 2017, Delinia became a subsidiary of Celgene Corporation, further strengthening its position in the biotechnology landscape.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Altamira Therapeutics is focused on developing innovative pharmaceutical therapies aimed at addressing unmet medical needs, particularly in neurotologic disorders affecting the inner ear. The company is recognized as a pioneer in creating treatments for hearing protection, tinnitus relief, and balance restoration. Among its product offerings is Bentrio, a drug-free nasal spray designed to provide personal protection against airborne viruses and allergens. Additionally, Altamira utilizes its OligoPhore/SemaPhore platform, which enables the complexation of therapeutic RNAs with proprietary peptides to create nanoparticle formulations. This technology facilitates the systemic delivery of therapeutic RNA to tissues impacted by leaky vasculature, which is characteristic of solid tumors and certain inflammatory conditions.

Creabilis is a European specialty pharmaceutical company focused on developing and commercializing innovative treatments for dermatological and inflammatory diseases. The company has a strong emphasis on addressing significant unmet medical needs in skin disorders, which presents high commercial potential. Its most advanced product is CT327, a topical treatment aimed at chronic pruritus, which is set to enter Phase II clinical trials. Creabilis also aims to establish a pruritus franchise around CT327 and another candidate, CT340, both developed using its proprietary Low Systemic Exposure platform technology. Additionally, Creabilis has a robust pipeline of clinical and pre-clinical drug candidates generated from its extensive research in dermatology.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.